1. Home
  2. TMC vs CDNA Comparison

TMC vs CDNA Comparison

Compare TMC & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TMC the metals company Inc.

TMC

TMC the metals company Inc.

HOLD

Current Price

$3.96

Market Cap

1.8B

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$45.46

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMC
CDNA
Founded
2011
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2020
2007

Fundamental Metrics

Financial Performance
Metric
TMC
CDNA
Price
$3.96
$45.46
Analyst Decision
Strong Buy
Buy
Analyst Count
5
6
Target Price
$8.85
$28.00
AVG Volume (30 Days)
4.6M
1.1M
Earning Date
05-12-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
232.00
N/A
EPS
0.19
2.13
Revenue
N/A
$48,324,000.00
Revenue This Year
N/A
$16.01
Revenue Next Year
N/A
$11.31
P/E Ratio
$19.84
$21.77
Revenue Growth
N/A
18.93
52 Week Low
$3.40
$11.27
52 Week High
$11.35
$49.76

Technical Indicators

Market Signals
Indicator
TMC
CDNA
Relative Strength Index (RSI) 45.81 63.69
Support Level $3.89 $16.70
Resistance Level $4.81 $49.76
Average True Range (ATR) 0.27 2.29
MACD 0.02 -0.39
Stochastic Oscillator 36.51 70.31

Price Performance

Historical Comparison
TMC
CDNA

About TMC TMC the metals company Inc.

TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: